CN1286503C - A Chinese medicinal composition with blood sugar and blood lipid reducing effects, and its preparation method - Google Patents
A Chinese medicinal composition with blood sugar and blood lipid reducing effects, and its preparation method Download PDFInfo
- Publication number
- CN1286503C CN1286503C CN 200410071035 CN200410071035A CN1286503C CN 1286503 C CN1286503 C CN 1286503C CN 200410071035 CN200410071035 CN 200410071035 CN 200410071035 A CN200410071035 A CN 200410071035A CN 1286503 C CN1286503 C CN 1286503C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- rapidly
- relative density
- reduced pressure
- under reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 55
- 239000008280 blood Substances 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 150000002632 lipids Chemical class 0.000 title abstract description 10
- 230000001603 reducing effect Effects 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 36
- 229940046374 chromium picolinate Drugs 0.000 claims abstract description 14
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 73
- 239000002775 capsule Substances 0.000 claims description 40
- 239000000284 extract Substances 0.000 claims description 30
- 238000001035 drying Methods 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 17
- 241000180649 Panax notoginseng Species 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- -1 chromium picolinates Chemical class 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000000643 oven drying Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000890 drug combination Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000007812 deficiency Effects 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 244000302512 Momordica charantia Species 0.000 abstract 1
- 235000009811 Momordica charantia Nutrition 0.000 abstract 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 abstract 1
- 235000018365 Momordica dioica Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 229930186217 Glycolipid Natural products 0.000 description 37
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 35
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- 239000008103 glucose Substances 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 23
- 108010023302 HDL Cholesterol Proteins 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 10
- 201000001421 hyperglycemia Diseases 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000037920 primary disease Diseases 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 230000003419 expectorant effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010020710 Hyperphagia Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 208000022530 polyphagia Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 108700022737 rat Fat1 Proteins 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- PMUIBVMKQVKHBE-UHFFFAOYSA-N [S].NC(N)=O Chemical compound [S].NC(N)=O PMUIBVMKQVKHBE-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition with the functions of regulating blood sugar and blood fat and a preparation method thereof. The pharmaceutical composition comprises gynostemma pentaphylla, fresh balsam pear, rhizoma polygonati, mulberry leaf, hawthorn, pseudo-ginseng, lotus leaf and chromium picolinate; is especially suitable for patients with diabetes and hyperlipidemia due to deficiency of both qi and yin, blood stasis, and turbid lipid stagnation; the preparation realized by the invention is stable and has definite curative effect.
Description
Invention field
The present invention relates to a kind of Chinese medicine composition and preparation method thereof, particularly a kind of Chinese medicine composition and preparation method thereof with blood sugar regulation, blood fat.
Background technology
Diabetes spp Chinese medicine diabetes category.The traditional Chinese medical science thinks that diabetes is mainly due to the plain body deficiency of YIN, and is multiple because of eating and drinking without temperance, and disorder of emotion is due to labor is desired excessively.One is eating and drinking without temperance, long-pending thermal burn Tianjin.Long-term surfeit delicious food, pure wine savoury and pungent stimulation food cause the transporting and transforming function of the spleen and stomach dereliction of duty, accumulate in the long-pending heat, and dryness-transformation impairment of body fluid, body fluid must not four cloth, and the internal organs meridians all lose to moisten and support and send out to quenching one's thirst; Two is innate deficiency, the five internal organs weakness.The natural endowment deficiency, the five internal organs fragility is related closely with primary disease, and wherein the effect of deficiency of kidney-essence in primary disease takes place is particularly outstanding.Kidney controlling essence storage is subjected to the essence of five ZANG-organs and six FU-organs and hides it, and the five internal organs weakness thanks to causes kidney essense and loses fewly in the QI and blood, or the vital essence deficiency of congenital kidney all can cause production of dryness-heat in the interior and sends out to quenching one's thirst; Three is that feelings will is uncomfortable, the stagnated fire impairment of YIN.Secular direct stimulation causes mechanism of qi pent-up, and then fire-transformation, and is intimately flourishing, the lung stomach-Yin Tianjin of upward burning, and the liquid of following bright Liver and kidney is sent out to quenching one's thirst; Four is the excess of sexual intercourse deficiency of the kidney.Constitution of YIN-deficiency, chamber does not save, impairment caused by overstrain is excessive, more consumes cloudy Tianjin, damage of kidney-YIN, hyperactivity of fire caused by deficiency of YIN, on steam the lung stomach, suffer from a deficiency of the kidney all now with causing with the dryness of the lung, gastric heat, send out to quenching one's thirst; Five was clothes warm-dryness syndrome Yang invigorating medicine, consumption impairment of YIN Tianjin.Take the warm-dryness syndrome Yang invigorating medicine for a long time in a large number, or prolonged illness wrongly takes the product of warm-dryness syndrome, cause production of dryness-heat in the interior, YIN fluid deficiency and give birth to and quench one's thirst.As seen the main pathology of primary disease is scorching inclined to one side victory, cloudy body fluid deficiency consumption.And be this with the deficiency of YIN, scorchingly be mark.The pathological changes internal organs are mainly at lung, stomach, kidney, and closely related with the liver failing to maintain the normal flow of QI.Diabetes with the passing of time, consumption impairment of QI Tianjin, deficiency of YIN affecting YANG, visible impairment of both QI and YIN or deficiency in both YIN and YANG, and be that the basic pathology that runs through the overall process of disease changes with deficiency of both QI and YIN.The unable blood of agitating of the deficiency of vital energy is capable, and then QI and blood is with tired, and QI-blood circulation slowly then stagnates and forms the stasis of blood.Therefore, deficiency of both QI and YIN, stopping in the blood stasis can be respectively or come across the different phase of the Different Individual of primary disease simultaneously.
Hyperlipemia motherland medical science belongs to it " phlegm-damp " " turbid resistance ", " blood stasis " category.Chinese medicine thinks that the generation of primary disease is relevant with factors such as age, diet, heredity, body constitution, and is dirty in close relations with liver,spleen,kidney three.Plain body deficiency of spleen-QI, the fortuneization malfunction causes giving birth in the phlegm-damp, stays in the turbid fat; The hepatic and renal YIN deficiency, excessive rising of liver-YANG, wooden prosperous gram spleen soil, spleen and stomach function is impaired, and fortuneization mistake department is expectorant Re Neisheng then.Said as Zhang Jingyue: " change of expectorant, invariably at spleen, the basis of expectorant is invariably at kidney ".Give birth in expectorant is turbid, hinder, turbid damp and the blood knot of fighting mutually in the arteries and veins, blockage of the vessel and form the disease of the mutual group of the expectorant stasis of blood in venation." the many stasis of bloods of prolonged illness ", " phlegm-damp ", " turbid resistance " with the passing of time must influence functional activity of QI being not smooth, and the stagnation of QI then blood stasis must be given birth to.So the sick position of primary disease is dirty at spleen, liver, kidney three, basic pathology is that visceral dysfunction, cream fat defeatedization are unfavorable, and mainly pathological factor is phlegm-damp, turbid fat, blood stasis.
Diabetes and hyperlipemia have the relation of close reciprocal causation.The traditional Chinese medical science is in secular clinical practice, use dialectical treatment diabetes and the hyperlipemia of combining with differential diagnosis of diseases to accumulate rich experience, therefore, fully excavate the rich experiences of Chinese medicine diabetes and hyperlipemia, in conjunction with research and the Chinese medicine latest developments of modern medicine to primary disease, develop a kind of determined curative effect, cheap, be fit to China's national situation, carry taking convenience, the treatment diabetes that have no side effect and the Chinese patent medicine of hyperlipemia, have important theoretical meaning and value for clinical application, and will fill up the blank in this field, for numerous patients and family bring glad tidings, have vast market prospect, will produce good economic benefit and social benefit.
Summary of the invention
One object of the present invention is to disclose a kind of Chinese medicine composition; Another object of the present invention is to disclose a kind of Chinese medicine composition with blood sugar regulation, blood fat; The 3rd purpose of the present invention is to disclose a kind of preparation method of Chinese medicine composition.
Pharmaceutical composition of the present invention is made (by weight) by following crude drug:
The bright Fructus Momordicae charantiae 60-100 of Herb Gynostemmae Pentaphylli 3-7 weight portion weight portion Rhizoma Polygonati 2-4 weight portion
Folium Mori 2-4 weight portion Fructus Crataegi 2-4 weight portion Radix Notoginseng 1-3 weight portion
Folium Nelumbinis 1-3 weight portion chromium picolinate 0.002-0.003 weight portion
The crude drug optimum ratio of pharmaceutical composition of the present invention is (by weight):
The bright Fructus Momordicae charantiae 80 weight portion Rhizoma Polygonatis of Herb Gynostemmae Pentaphylli 5 weight portions 3 weight portions
Folium Mori 3 weight portion Fructus Crataegis 3 weight portion Radix Notoginseng 2 weight portions
Folium Nelumbinis 2 weight portion chromium picolinates 0.0024 weight portion
The crude drug optimum ratio of pharmaceutical composition of the present invention is (by weight):
The bright Fructus Momordicae charantiae 65 weight portion Rhizoma Polygonatis of Herb Gynostemmae Pentaphylli 6.5 weight portions 3.5 weight portions
Folium Mori 2.5 weight portion Fructus Crataegis 3.5 weight portion Radix Notoginseng 1.5 weight portions
Folium Nelumbinis 2.5 weight portion chromium picolinates 0.0021 weight portion
It is (by weight) that the crude drug of pharmaceutical composition of the present invention is formed optimum ratio:
The bright Fructus Momordicae charantiae 90 weight portion Rhizoma Polygonatis of Herb Gynostemmae Pentaphylli 3.5 weight portions 2.5 weight portions
Folium Mori 3.5 weight portion crataegus pin natifida var. Major 2.5 weight portion Radix Notoginseng 2.5 weight portions
Folium Nelumbinis 1.5 weight portion chromium picolinates 0.0028 weight portion
This preparation of drug combination method:
Folium Mori are soaked, decoct 2-3 time, amount of water is 10-15 times, each 1-2 hour, filter merging filtrate, relative density was 1.20～1.25 thick paste when concentrating under reduced pressure was 60 ℃, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition gets dry extract, and inserts clean container A rapidly; Herb Gynostemmae Pentaphylli, Rhizoma Polygonati, Fructus Crataegi, Folium Nelumbinis are soaked, and amount of water is 6-12 times, decocts 2-3 time, each 1-2 hour, filter merging filtrate, relative density is 1.04～1.08 clear paste during 60 ℃ of simmer down tos, and adding ethanol to determining alcohol is 60%, leaves standstill, filter, receive alcohol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container B rapidly; Bright Fructus Momordicae charantiae section decocts 2-3 time, and amount of water is 2-3 times, each 1-2 hour, filter merging filtrate, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, and drying under reduced pressure gets dry extract under pressure 0.08Mpa, 60 ± 1 ℃ of temperature, 10 hours time condition, inserts clean container C rapidly; Radix Notoginseng powder is broken into coarse grain, add 60% soak with ethanol, extract secondary, alcohol adding amount is 6-8 times, each 1-2 hour, filter, merging filtrate reclaims ethanol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition gets dry extract, and inserts clean container D rapidly; Chromium picolinate, 75% ethanol is moistening, waves to there not being the alcohol flavor, and oven drying at low temperature below 80 ℃ is inserted clean container E rapidly; Material merges and pulverizes in A, B, C, the D, mixing, again with E in material evenly mixed, this pharmaceutical composition, this pharmaceutical composition can be made into clinical acceptable forms, comprises tablet, granule, capsule, oral liquid, drop pill etc.
The preparation functional component that the present invention makes is total flavones, total Saponin, chromium picolinate, and wherein every restraint agent contains total flavones (in rutin) and is no less than 7.9mg, contains total Saponin (in the ginsenoside Re) and be no less than 16.3mg, contain chromium picolinate and be no less than 0.51mg.
The present invention is exclusively used in diabetes, the hyperlipemia card belongs to deficiency of both QI and YIN, stagnation of blood stasis, turbid fat inner stopper.Treatment based on supplementing QI and nourishing YIN, transfer smooth QI and blood, change turbid blood fat reducing.The preparation stabilization that the present invention realizes, quality controllable.
The pharmacodynamics of the capsule preparations (glycolipid peace capsule) that Chinese medicine composition of the present invention is made is partly studied, the result shows: fasting glucose 1.37 ± 1.72mmol/L post-prandial glycemia, the 0.74 ± 1.99mmol/L that on average descends that descends after month, total effective rate 70.00% illustrates that glycolipid peace capsule blood sugar lowering has certain effect; To examination trencherman polyphagia, polydipsia, polyuria, weak, etc. cardinal symptom, have a better role; Tried thing the carbohydrate tolerance of alloxan induced hyperglycemia mice is had regulating action; Compare with the control rats of the high lipid food of feeding, in giving. the glycolipid of high dose peace capsule can make rat blood serum T-CHOL (TC) concentration significantly descend (P＜0.05, P＜0.01) "; The glycolipid peace capsule that gives middle and high dosage can make rat blood serum triglyceride (TC) concentration significantly descend (P＜0.05, P＜0.01); 0.3 day, 0.75, the glycolipid of 2.25g.Bw dosage peace capsule to irritate stomach, after the 28th day, serum TC is respectively 6.6,13.3,17.8 than matched group decline percentage rate: with 0.38,0.75, the glycolipid peace capsule of 2.25g/kg.BW dosage irritates and emit serum TG than matched group decline percentage rate respectively 6.5,10.2,12.6: show that being tried thing has the blood lipid regulation effect.Following experimental example is used to further specify the present invention:
Experimental example 1 glycolipid peace capsule blood sugar lowering effect human experiment is observed
Observe 60 examples altogether, southern board glycolipid peace Capsules group male 7 examples of cloud, women's 23 examples, minimum 43 years old of age, the oldest 65 years old, average 53.80 years old, average course of disease 6.02 years; Matched group male 13 examples, women's 17 examples, minimum 30 years old of age, maximum 65 years old, average 53.13 years old, average course of disease 6.33 years.
Two groups observe last as situation relatively:
Situation comparison as table 1. observation is last (X ± SD)
| Grouping | Example number (example) | Age (year) | Sex | The course of disease (year) | Blood glucose (mmol/L) | ||
| The man | The woman | On an empty stomach | 2 hours after the meal | ||||
| Glycolipid peace group matched group | 30 30 | 53.80±6.38 53.13±9.42 | 7 13 | 23 17 | 6.02±4.09 6.33±4.35 | 9.67±2.16 9.80±2.65 | 14.05±3.04 13.36±3.34 |
Table 2. examination trencherman takes the hypoglycemic medicine situation
| Grouping | The example number | Sulphanylureas | Biguanides | Sulphur urea+biguanides | Do not take |
| Glycolipid peace group matched group | 30 30 | 11 8 | 8 8 | 5 9 | 4 5 |
By table 1, table 2 as seen, every index no significant difference before two groups of test-meals has comparability.
2. blood sugar lowering effect:
(1) clinical observation
The variation of clinical symptoms before and after table 3. test-meal
| Symptom | Produce effects (example) | Effectively (example) | Invalid (example) | Improvement rate % | ||||
| Matched group | Observation group | Matched group | Observation group | Matched group | Observation group | Matched group | Observation group | |
| The weak polyphagia of polydipsia polyuria | 2 1 1 2 | 0 0 1 0 | 3 7 3 4 | 5 5 8 5 | 6 10 11 10 | 5 4 7 5 | 45.45 44.44 26.67 37.50 | 50.00 55.56 56.25 50.00 |
Table 4. effect relatively
| Group | The example number | Effectively | Invalid | Total effective rate % | ||
| The example number | ％ | The example number | ％ | |||
| Glycolipid peace group matched group | 30 30 | 21 9 | 70.00 30.00 | 9 21 | 30.00 70.00 | 70.00# 30.00 |
Contrast #P＜0.05 between group
(2) empty stomach and post-prandial glycemia are relatively:
Fasting glucose comparison before and after the table 5. liang group test-meal (mmol/L, X ± SD)
| Grouping | Fasting glucose | ||
| Before the test-meal | After the test-meal | Difference | |
| Glycolipid peace group matched group | 9.67±2.16 9.80±2.65 | 8.29±2.56 9.61±2.88 | -1.37±1.72** -0.19±1.35## |
Contrast ##P＜0.01 between own control * * P＜0.01 group
After one month, the southern board glycolipid peace Capsules group fasting glucose decline 1.37mmol/L of cloud, the matched group fasting glucose descends not obvious, and two groups relatively have notable difference.
Blood glucose comparison in 2 hours after the meal before and after the table 6. liang group test-meal (mmol/L, X ± SD)
| Grouping | 2 hours after the meal blood glucose | ||
| Before the test-meal | After the test-meal | Difference | |
| Glycolipid peace group matched group | 14.05±3.04 13.36±3.34 | 13.31±2.96 13.81±3.67 | -0.74±1.99* 0.45±2.06# |
Contrast #P＜0.05 between own control * P＜0.05 group
After one month, 2 hours after the meal blood glucose decline 0.74mmol/L of southern board glycolipid peace Capsules group of cloud, the blood glucose decline in 2 hours after the meal of own control significant difference, matched group is not obvious, and two groups relatively have notable difference.
3. sum up: the southern board glycolipid peace capsule of cloud has comparatively significantly blood sugar lowering effect, fasting glucose 1.37 ± 1.72mmol/L post-prandial glycemia, the 0.74 ± 1.99mmol/L that on average descends that descends after month, wherein effective 21 examples, total effective rate 70.00%; Matched group empty stomach and post-prandial glycemia descend all not obvious, wherein effective 9 examples, and 30.00%, two group relatively there were significant differences for total effective rate, illustrates that the southern board glycolipid peace capsule blood sugar lowering of cloud has certain effect; To examination trencherman polyphagia, polydipsia, polyuria, weak, etc. cardinal symptom, have a better role.
Experimental example 2 glycolipids peace capsule hypoglycemic activity examining report
1. test method:
Select the healthy adult female mice, after the fasting 24 hours, give lumbar injection alloxan (100mg/kgBW), in injection back fasting in the 7th day 5 hours, freely drink water, measure fasting blood sugar, select fasting glucose greater than 40 of the mices of 10mmol/L, be divided into four groups at random according to blood sugar level, i.e. model control group and three dosage groups being tried thing.Observation is tried thing to the fasting glucose of alloxan induced hyperglycemia mice and the influence of carbohydrate tolerance.
Date processing: result of the test adopts SPSS 8.0 software processes (t check), and data are with the formal representation of X ± S.
2. result of the test
(1) the southern board glycolipid peace capsule of cloud is to the influence of hyperglycemia mice fasting glucose.(seeing Table 7)
The southern board glycolipid peace capsule of table 7 cloud is to the influence of hyperglycemia mice fasting glucose
| Group | Dosage (mg/kgBW) | Number of animals (only) | Fasting blood sugar (mol/L) | ||
| Before the test | After the test | The P value | |||
| Dosage high dose in the model contrast low dosage | - 75 750 2250 | 10 10 10 10 | 19.15±4.20 18.92±4.19 19.15±4.24 19.48±4.00 | 16.53±3.57 15.78±3.11 13.81±2.30* 12.26±1.30** | - 0.540 0.031 0.001 |
Annotate: compare with model control group: P＜0.05, *; P＜0.01, * *.
By the listed result of table 7 as seen, the fasting glucose there was no significant difference of each treated animal before the test, the fasting blood sugar of the middle and high dosage treated animal in test back is starkly lower than model control group, learns check by statistics, and difference has significance.Illustrate that this is tried thing and can reduce fasting glucose by the alloxan induced hyperglycemia mice.
(2) the southern board glycolipid peace capsule of cloud is to the influence of hyperglycemia mice post-prandial glycemia.(seeing Table 8)
The southern board glycolipid peace capsule of table 8 cloud is to the influence of hyperglycemia mice post-prandial glycemia
| Group | Dosage (mg/kgBW) | Number of animals (only) | Glucose (mg/kgBW) | Blood glucose value (mol/L) | ||
| 0h | 0.5h | 2h | ||||
| Dosage high dose in the model contrast low dosage | - 75 750 2250 | 10 10 10 10 | 2.0 2.0 2.0 2.0 | 16.53±3.57 15.78±73.11 13.81±2.30* 12.26±1.30** | 27.64±4.04 26.97±2.54 22.20±4.24** 17.89±1.48** | 25.75±4.56 23.48±3.25 19.110±4.62** 14.39±1.72** |
Annotate: compare with model control group: P＜0.05, *; P＜0.01, * *.
By the listed result of table 8 as seen, 2 hours blood glucose all was starkly lower than model control group after middle and high dosage treated animal gave behind the glucose 0.5 hour blood glucose and gives glucose, learned check by statistics, and difference has significance.
(3) the southern board glycolipid peace capsule of cloud is to the influence of hyperglycemia mice carbohydrate tolerance.(seeing Table 9)
The southern board glycolipid peace capsule of table 9 cloud is to the influence of hyperglycemia mice carbohydrate tolerance
| Group | Dosage (mg/kgBW) | Number of animals (only) | Blood sugar increasing and reduction amplitude (mol/L) | |||
| 0.5h-0h | The P value | 0.5h-2h | The P value | |||
| Dosage high dose in the model contrast low dosage | - 75 750 2250 | 10 10 10 10 | 11.11±1.40 11.19±1.71 8.39±2.10** 5.63±0.48** | - 0.908 0.000 0.000 | 1.89±0.95 3.49±0.99** 3.09±0.74** 3.50±0.78** | - 0.000 0.004 0.000 |
Annotate: compare with model control group: P＜0.01, * *.
By the listed result of table 9 as seen, middle and high dosage group gives the rising amplitude of 0.5 hour blood glucose behind the glucose and all is starkly lower than model control group and each dosage group and gives that the reduction amplitude of 2 hours blood glucose all is higher than model control group behind the glucose, learn check by statistics, difference has significance.Illustrate that this is tried thing the carbohydrate tolerance of alloxan induced hyperglycemia mice is had regulating action.
Experimental example 3 glycolipids peace capsule blood lipid regulation zoopery report
1. experimental technique:
After 5 days, fasting is weighed with normal feedstuff feed rat, gets tail blood, enzymatic assays serum total cholesterol (TC), triglyceride (TG), HDL-C (HDL-C).According to body weight, TC level animal is divided into 4 groups at random: matched group, 3 are tried thing group (0.38g/kg.BW; 0.75g/kg.BW; 2.25g/kg.Bw).Begin from formal test, each treated animal is used high lipid food instead, is recognized thing and is assigned to desired concn with distilled water.Tried thing to irritate the stomach mode, matched group gives distilled water.Got the every blood lipids index of tail hematometry respectively at the 14th, 28 day.
Experimental data statistics: carry out variance analysis with SPSS software.Variance is neat, and P＞0.05 shows respectively to organize does not have significant difference between mean; Mean comparative statistics P≤0.05 between matched group and experimental group shows that difference has significance.
2. result
(1) the southern board glycolipid peace capsule of cloud is to the influence of rat body weight
It is normal that whole experimental session is respectively organized the rat growth.By table 10 as seen, each experimental group rat body weight and control rats body weight zero difference (P＞0.05).
Respectively organize body weight (g, the M ± SD) of rat in table 10. experiment initial stage, mid-term, latter stage
| Group | Number of animals | Dosage | The initial stage body weight | Mid-term body weight | Latter stage body weight |
| (only) | (g/kg.BW) | ||||
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 0 0.38 0.75 2.25 | 195.9±5.9 197.2±6.0 196.6±5.0 196.3±5.5 | 270.4±10.7 273.6±15.7 274.1±15.1 272.3±12.7 | 317.7±19.9 321.9±22.1 317.6±16.6 314.3±14.7 |
(2) the southern board glycolipid peace capsule of cloud is to the influence of rat blood serum T-CHOL (TC) concentration
By table 11 as seen, compare with matched group latter stage in experiment, middle and high dosage group rat blood serum T-CHOL (TC) concentration significantly reduces (P＜0.01).
Respectively organize serum TC concentration (mmol/L, M ± SD) in table 11. experiment initial stage, mid-term, latter stage
| Group | Number of animals | The experiment initial stage | Test mid-term | Test latter stage |
| (only) | ||||
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 2.02±0.30 2.07±0.17 2.03±0.29 2.02±0.18 | 2.26±0.22 2.23±0.19 2.13±0.25 2.07±0.24 | 2.41±0.27 2.25±0.28 2.09±0.32* 1.98±0.30** |
Compare * P＜0.05 with matched group, * * P＜0.01
(3) the southern board glycolipid peace capsule of cloud is to the influence of rat blood serum triglyceride (TG) concentration
By table 12 as seen, serum triglycerides (TG) level of experiment middle and high dosage group rat in latter stage is compared remarkable reduction with matched group, and the difference (P＜0.01) on the statistics is arranged.
Respectively organize serum TG concentration (mmol/L, M ± SD) in table 12. experiment initial stage, mid-term, latter stage
| Group | Number of animals | The experiment initial stage | Test mid-term | Test latter stage |
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 1.84±0.22 1.82±0.29 1.82±0.18 1.86±0.15 | 2.08±0.32 1.96±0.26 1.93±0.17 1.89±0.10 | 2.15±0.31 2.01±0.27 1.93±0.21* 1.88±0.17** |
Compare with matched group: * P＜0.05, * * P＜0.01
(4) the southern board glycolipid peace limb capsule of cloud is to the influence of rat blood serum HDL-C (HDL-C) concentration
By table 13 as seen, each experimental group rat blood serum HDL-C (HDL-C) concentration and right is according to organizing the difference of comparing on the no statistics (P＞0.05).
Table 13. test initial stage, mid-term, the phase is not respectively organized Serum HDL-C concentration (mmol/L, M ± SD)
| Group | Number of animals (only) | The experiment initial stage | Test mid-term | Test latter stage |
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 1.47±0.14 1.42±0.20 1.44±0.20 1.44±0.18 | 1.26±0.17 1.20±0.19 1.22±0.14 1.19±0.18 | 1.11±0.14 1.04±0.09 1.04±0.10 1.04±0.12 |
(5) the southern board glycolipid peace capsule of cloud has reflected the ratio of cardiovascular " the protection factor " HDL-C in TC to HDL-C/total gallbladder circle alcohol (HDL-C/TC) ratio that influences of rat blood serum HDL-C/T-CHOL (HDL-C/TC) ratio; by table 14 as seen, the HDL-C/TC ratio there was no significant difference (P＞0.05) of each group.
Respectively organize Serum HDL-C/TC ratio (M ± SD) in table 14. experiment initial stage, mid-term, latter stage
| Group | Number of animals (only) | The experiment initial stage | Test mid-term | Test latter stage |
| Dosage group high dose group in the matched group low dose group | 10 10 10 10 | 0.74±0.12 0.70±0.15 0.72±0.14 0.71±0.08 | 0.57±0.11 0.54±0.10 0.58±0.09 0.58±0.12 | 0.47±0.10 0.47±0.08 0.51±0.08 0.54±0.10 |
(6) the southern board glycolipid peace capsule of cloud is to the influence of rat fat level
By table 15 as seen, with 0.38,0.75, the southern board glycolipid peace capsule of the cloud of 2.25g/kg.BW dosage irritates stomach, after the 28th day, serum TC is respectively 6.6,13.3,17.8 than matched group decline percentage rate; With 0.38,0.75, the southern board glycolipid peace capsule of the cloud of 2.25g/kg.BW dosage irritates stomach, serum TG is than matched group decline percentage rate respectively 6.5,10.2,12.6.
The southern board of table 15 cloud is warded off the influence of fat recovering capsule to the rat fat level
| Group | TC (％) | TG (％) | HDL-C (％) |
| Dosage group high dose group in the low dose group | 6.6 -13.3 -17.8 | -6.5 -10.2 12.6 | -6.3 -6.3 -6.3 |
3, brief summary
This experimental result shows, compares with the control rats of the high lipid food of feeding, in giving. the southern board glycolipid peace capsule of the cloud of high dose can make rat blood serum T-CHOL (TC) concentration significantly descend (P＜0.05, P＜0.01); The southern board glycolipid peace capsule that gives the cloud of middle and high dosage can make rat blood serum triglyceride (TC) concentration significantly descend (P＜0.05, P＜0.01).Each experimental group rat blood serum HDL-C (HDL-C) concentration is compared the difference (P＞0.05) on the no statistics with matched group.HDL-C/T-CHOL (HDL-C/TC) ratio has reflected the ratio of cardiovascular " the protection factor " HDL-C in TC, the HDL-C/TC ratio there was no significant difference (P＞0.05) of each group.0.3 day, 0.75, the southern board glycolipid peace capsule of the cloud of 2.25g.Bw dosage to irritate stomach, after the 28th day, serum TC is respectively 6.6,13.3,17.8 than matched group decline percentage rate: with 0.38,0.75, the southern board glycolipid peace capsule of the cloud of 2.25g/kg.BW dosage irritates the stomach serum TG than matched group decline percentage rate respectively 6.5,10.2,12.6.According to the criterion of blood lipid regulation in " the health food function assessment assessment process and the method for inspection ", can think that the southern board grain fat recovering capsule of cloud has the blood lipid regulation effect.
Embodiment 1:
The bright Fructus Momordicae charantiae 80kg of Herb Gynostemmae Pentaphylli 5kg Rhizoma Polygonati 3kg Folium Mori 3kg
Fructus Crataegi 3kg Radix Notoginseng 2kg Folium Nelumbinis 2kg chromium picolinate 2.4g
Folium Mori are soaked, decoct 3 times, amount of water is 15 times, 10 times, 10 times, each 1 hour, filter merging filtrate, relative density was 1.20～1.25 thick paste when concentrating under reduced pressure was 60 ℃, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition gets dry extract, and inserts clean container A rapidly; Herb Gynostemmae Pentaphylli, Rhizoma Polygonati, Fructus Crataegi, Folium Nelumbinis are soaked, and amount of water is 10 times, 8 times, 8 times, decoct each 1 hour 3 times, filter, relative density is 1.04～1.08 clear paste when merging filtrate, 60 ℃ of simmer down tos, adding ethanol to determining alcohol is 60%, leaves standstill, and filters, receive alcohol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container B rapidly; Bright Fructus Momordicae charantiae section decocts 2 times, and amount of water is 2 times, 2 times, each 1 hour, filter merging filtrate, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, and drying under reduced pressure gets dry extract under pressure 0.08Mpa, 60 ± 1 ℃ of temperature, 10 hours time condition, inserts clean container C rapidly; Radix Notoginseng powder is broken into coarse grain, adds 60% soak with ethanol, extracts secondary, alcohol adding amount is 8 times, 6 times, each 1.5 hours, filter, merging filtrate, reclaim ethanol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container D rapidly; Chromium picolinate, 75% ethanol is moistening; Wave to there not being the alcohol flavor, oven drying at low temperature below 80 ℃ 3 hours is inserted clean container E rapidly; Material merges and pulverizes in A, B, C, the D, mixing, again with E in material evenly mixed; Load No. 0 capsule.Through moisture, loading amount after the assay was approved, 9000 capsules are made in bottling altogether.Every day 3 times, each 3, the 0.5g/ grain.
Embodiment 2:
The bright Fructus Momordicae charantiae 65kg of Herb Gynostemmae Pentaphylli 6.5kg Rhizoma Polygonati 3.5kg Folium Mori 2.5kg
Fructus Crataegi 3.5kg Radix Notoginseng 1.5kg Folium Nelumbinis 2.5kg chromium picolinate 2.1g
Folium Mori are soaked, decoct 3 times, amount of water is 10 times, 10 times, 15 times, each 1.5 hours, filter merging filtrate, relative density was 1.20～1.25 thick paste when concentrating under reduced pressure was 60 ℃, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition gets dry extract, and inserts clean container A rapidly; Herb Gynostemmae Pentaphylli, Rhizoma Polygonati, Fructus Crataegi, Folium Nelumbinis are soaked, and amount of water is 10 times, 8 times, 8 times, decoct each 1.5 hours 3 times, filter, relative density is 1.04～1.08 clear paste when merging filtrate, 60 ℃ of simmer down tos, adding ethanol to determining alcohol is 60%, leaves standstill, and filters, receive alcohol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container B rapidly; Bright Fructus Momordicae charantiae section decocts 2 times, and amount of water is 2 times, 3 times, each 1 hour, filter merging filtrate, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, and drying under reduced pressure gets dry extract under pressure 0.08Mpa, 60 ± 1 ℃ of temperature, 10 hours time condition, inserts clean container C rapidly; Radix Notoginseng powder is broken into coarse grain, adds 60% soak with ethanol, extracts secondary, alcohol adding amount is 8 times, 6 times, each 1 hour, filter, merging filtrate, reclaim ethanol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container D rapidly; Chromium picolinate, 75% ethanol is moistening; Wave to there not being the alcohol flavor, oven drying at low temperature below 60 ℃ 4 hours is inserted clean container E rapidly; Material merges and pulverizes in A, B, C, the D, mixing, again with E in material evenly mixed; Make 9 altogether according to conventional method.Every day 3 times, each 3.
Embodiment 3:
The bright Fructus Momordicae charantiae 90kg of Herb Gynostemmae Pentaphylli 3.5kg Rhizoma Polygonati 2.5kg Folium Mori 3.5kg
Fructus Crataegi 2.5kg Radix Notoginseng 2.5kg Folium Nelumbinis 1.5kg chromium picolinate 2.8g
Folium Mori are soaked, decoct 2 times, amount of water is 10 times, 15 times, each 2 hours, filter merging filtrate, relative density was 1.20～1.25 thick paste when concentrating under reduced pressure was 60 ℃, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition gets dry extract, and inserts clean container A rapidly; Herb Gynostemmae Pentaphylli, Rhizoma Polygonati, Fructus Crataegi, Folium Nelumbinis are soaked, and amount of water is 10 times, 6 times, 8 times, decoct each 1.5 hours 2 times, filter, relative density is 1.04～1.08 clear paste when merging filtrate, 60 ℃ of simmer down tos, adding ethanol to determining alcohol is 60%, leaves standstill, and filters, receive alcohol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container B rapidly; Bright Fructus Momordicae charantiae section, decoct 3 times, amount of water is 2 times, 3 times, and 2 times, each 2 hours, filter, relative density is 1.20～1.25 thick paste when merging filtrate, 60 ℃ of simmer down tos, drying under reduced pressure gets dry extract under pressure 0.08Mpa, 60 ± 1 ℃ of temperature, 10 hours time condition, inserts clean container C rapidly; Radix Notoginseng powder is broken into coarse grain, adds 60% soak with ethanol, extracts secondary, alcohol adding amount is 6 times, 8 times, each 1 hour, filter, merging filtrate, reclaim ethanol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container D rapidly; Chromium picolinate, 75% ethanol is moistening; Wave to there not being the alcohol flavor, oven drying at low temperature below 70 ℃ 3.5 hours is inserted clean container E rapidly; Material merges and pulverizes in A, B, C, the D, mixing, again with E in material evenly mixed; Make granule according to conventional method.
Claims (8)
1, a kind of Chinese medicine composition with blood sugar lowering, blood fat is characterized in that the crude drug of this Chinese medicine composition consists of:
The bright Fructus Momordicae charantiae 60-100 of Herb Gynostemmae Pentaphylli 3-7 weight portion weight portion Rhizoma Polygonati 2-4 weight portion
Folium Mori 2-4 weight portion Fructus Crataegi 2-4 weight portion Radix Notoginseng 1-3 weight portion
Folium Nelumbinis 1-3 weight portion chromium picolinate 0.002-0.003 weight portion.
2, Chinese medicine composition as claimed in claim 1 is characterized in that the crude drug of this Chinese medicine composition consists of:
The bright Fructus Momordicae charantiae 80 weight portion Rhizoma Polygonatis of Herb Gynostemmae Pentaphylli 5 weight portions 3 weight portions
Folium Mori 3 weight portion Fructus Crataegis 3 weight portion Radix Notoginseng 2 weight portions
Folium Nelumbinis 2 weight portion chromium picolinates 0.0024 weight portion.
3, Chinese medicine composition as claimed in claim 1 is characterized in that the crude drug of this Chinese medicine composition consists of:
The bright Fructus Momordicae charantiae 65 weight portion Rhizoma Polygonatis of Herb Gynostemmae Pentaphylli 6.5 weight portions 3.5 weight portions
Folium Mori 2.5 weight portion Fructus Crataegis 3.5 weight portion Radix Notoginseng 1.5 weight portions
Folium Nelumbinis 2.5 weight portion chromium picolinates 0.0021 weight portion.
4, Chinese medicine composition as claimed in claim 1 is characterized in that the crude drug of this Chinese medicine composition consists of:
The bright Fructus Momordicae charantiae 90 weight portion Rhizoma Polygonatis of Herb Gynostemmae Pentaphylli 3.5 weight portions 2.5 weight portions
Folium Mori 3.5 weight portion Fructus Crataegis 2.5 weight portion Radix Notoginseng 2.5 weight portions
Folium Nelumbinis 1.5 weight portion chromium picolinates 0.0028 weight portion.
5,, it is characterized in that this method is as the preparation method of claim 1,2,3 or 4 described Chinese medicine compositions:
Folium Mori are soaked, decoct 2-3 time, amount of water is 10-15 times, each 1-2 hour, filter merging filtrate, relative density was 1.20～1.25 thick paste when concentrating under reduced pressure was 60 ℃, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition gets dry extract, and inserts clean container A rapidly; Herb Gynostemmae Pentaphylli, Rhizoma Polygonati, Fructus Crataegi, Folium Nelumbinis are soaked, and amount of water is 6-12 times, decocts 2-3 time, each 1-2 hour, filter merging filtrate, relative density is 1.04～1.08 clear paste during 60 ℃ of simmer down tos, and adding ethanol to determining alcohol is 60%, leaves standstill, filter, receive alcohol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container B rapidly; Bright Fructus Momordicae charantiae section decocts 2-3 time, and amount of water is 2-3 times, each 1-2 hour, filter merging filtrate, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, and drying under reduced pressure gets dry extract under pressure 0.08Mpa, 60 ± 1 ℃ of temperature, 10 hours time condition, inserts clean container C rapidly; Radix Notoginseng powder is broken into coarse grain, add 60% soak with ethanol, extract secondary, alcohol adding amount is 6-8 times, each 1-2 hour, filter, merging filtrate reclaims ethanol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition gets dry extract, and inserts clean container D rapidly; Chromium picolinate, 75% ethanol is moistening, waves to there not being the alcohol flavor, and oven drying at low temperature below 80 ℃ is inserted clean container E rapidly; Material merges and pulverizes in A, B, C, the D, mixing, again with E in material evenly mixed, this pharmaceutical composition, this pharmaceutical composition is made the dosage form of clinical acceptance.
6, preparation of drug combination method as claimed in claim 5 is characterized in that this method is:
Folium Mori are soaked, decoct 3 times, amount of water is 15 times, 10 times, 10 times, each 1 hour, filter merging filtrate, relative density was 1.20～1.25 thick paste when concentrating under reduced pressure was 60 ℃, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition gets dry extract, and inserts clean container A rapidly; Herb Gynostemmae Pentaphylli, Rhizoma Polygonati, Fructus Crataegi, Folium Nelumbinis are soaked, and amount of water is 10 times, 8 times, 8 times, decoct each 1 hour 3 times, filter, relative density is 1.04～1.08 clear paste when merging filtrate, 60 ℃ of simmer down tos, adding ethanol to determining alcohol is 60%, leaves standstill, and filters, receive alcohol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container B rapidly; Bright Fructus Momordicae charantiae section decocts 2 times, and amount of water is 2 times, 2 times, each 1 hour, filter merging filtrate, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, and drying under reduced pressure gets dry extract under pressure 0.08Mpa, 60 ± 1 ℃ of temperature, 10 hours time condition, inserts clean container C rapidly; Radix Notoginseng powder is broken into coarse grain, adds 60% soak with ethanol, extracts secondary, alcohol adding amount is 8 times, 6 times, each 1.5 hours, filter, merging filtrate, reclaim ethanol, relative density is 1.20～1.25 thick paste during 60 ℃ of simmer down tos, drying under reduced pressure under pressure 0.08Mpa, 70 ± 1 ℃ of temperature, 8～10 hours time condition, get dry extract, insert clean container D rapidly; Chromium picolinate, 75% ethanol is moistening; Wave to there not being the alcohol flavor, oven drying at low temperature below 80 ℃ 3 hours is inserted clean container E rapidly; Material merges and pulverizes in A, B, C, the D, mixing, again with E in material evenly mixed; Filling capsule is made capsule.
7, as claim 1,2, the application of 3 or 4 described pharmaceutical compositions in the medicine of preparation treatment diabetes, hyperlipemia.
8, has application in the medicine of blood sugar lowering, blood fat as claim 1,2,3 or 4 described pharmaceutical compositions in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410071035 CN1286503C (en) | 2004-07-27 | 2004-07-27 | A Chinese medicinal composition with blood sugar and blood lipid reducing effects, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410071035 CN1286503C (en) | 2004-07-27 | 2004-07-27 | A Chinese medicinal composition with blood sugar and blood lipid reducing effects, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1726988A CN1726988A (en) | 2006-02-01 |
| CN1286503C true CN1286503C (en) | 2006-11-29 |
Family
ID=35926626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410071035 Expired - Lifetime CN1286503C (en) | 2004-07-27 | 2004-07-27 | A Chinese medicinal composition with blood sugar and blood lipid reducing effects, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1286503C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101053592B (en) * | 2007-05-29 | 2010-06-02 | 中食肽灵（北京）生物科技有限公司 | Medicinal composition for treating impaired glucose tolerance and preparation method thereof |
| CN103082298B (en) * | 2013-01-17 | 2014-08-13 | 吉林省中药制剂工程研究中心有限公司 | Health-care food for reducing blood glucose in assisted mode and preparation method thereof |
| CN104800411A (en) * | 2015-04-22 | 2015-07-29 | 淄博齐鼎立专利信息咨询有限公司 | Application of traditional Chinese medicinal composition to preparation of medicine for reducing blood glucose |
| CN105055968B (en) * | 2015-08-31 | 2019-02-15 | 李章训 | A kind of Chinese medicine composition that treating diabetes, preparation method and application |
| CN108741033A (en) * | 2018-06-11 | 2018-11-06 | 广东省阳春市信德生物科技发展有限公司 | It is a kind of that there is the blood fat clearing capsule formula for adjusting blood fat |
-
2004
- 2004-07-27 CN CN 200410071035 patent/CN1286503C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1726988A (en) | 2006-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102406860B (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN102187887B (en) | Sandwich biscuit with functions of losing weight and regulating blood sugar and production method thereof | |
| CN109221898A (en) | A kind of grain dust and its preparation method and application containing xylo-oligosaccharide | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN103829140A (en) | Cereal powder with functions of losing weight and reducing blood sugar | |
| CN1814167A (en) | Health-care for diabetes | |
| CN108392519A (en) | A kind of hypoglycemic composition and its preparation and application | |
| CN107212256A (en) | A kind of meal replacement powder with function of blood sugar reduction and preparation method thereof | |
| CN102614499A (en) | Yak skin collagen compound traditional Tibetan medicine with anti-fatigue effect and preparation process thereof | |
| CN106465946A (en) | A kind of loosening bowel to relieve constipation dietary fiber | |
| CN1762458A (en) | Hyperlipemia treating medicine and its preparation method | |
| CN1286503C (en) | A Chinese medicinal composition with blood sugar and blood lipid reducing effects, and its preparation method | |
| CN1706281A (en) | Health food with subsidiary function of lowering blood sugar and lowering blood fat and its production process | |
| CN103463407B (en) | Reason machine Jiangtang capsule | |
| CN102861201A (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN103736071A (en) | Composition having effect of assisting in decreasing blood sugar, and application and preparation method thereof | |
| CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
| CN105249441A (en) | Folium mori health care product for reducing blood glucose and preparation method thereof | |
| CN108935694A (en) | A kind of healthcare goat milk powder and preparation method thereof with antifatigue simultaneous void of enriching blood | |
| CN1234302C (en) | Health antihyperglycemia milk tea | |
| CN103960486B (en) | A kind of bird feed additive for producing health-care eggs | |
| CN1958035A (en) | Composition of medication in use for reducing blood sugar, blood fat, and treating diabetes | |
| CN113499366A (en) | Composition with function of reducing blood sugar and blood fat simultaneously and preparation method thereof | |
| CN102648746A (en) | Diet fiber composition with intestine-nourishing constipation-releving functions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN LONGRUN PHARMACEUTICAL CO.,LTD. Free format text: FORMER OWNER: JIAO JIALIANG Effective date: 20120308 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120308 Address after: 10 No. 650101 Road, hi tech Industrial Development Zone, Yunnan, Kunming Patentee after: YUNNAN LONGRUN PHARMACEUTICAL Co.,Ltd. Address before: 10 No. 650101 Road, hi tech Industrial Development Zone, Yunnan, Kunming Patentee before: Jiao Jialiang |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Combination of Chinese traditional medicine possessing function of regulating blood sugar, blood fat, preparation method Effective date of registration: 20160624 Granted publication date: 20061129 Pledgee: Fenghui Leasing Co.,Ltd. Pledgor: Yunnan LongRun Pharmaceutical Co.,Ltd. Registration number: 2016530000008 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061129 |
|
| CX01 | Expiry of patent term |